Parameter | Reference | Study characteristics | Association | OR (95% CI) | P value |
---|---|---|---|---|---|
Systemic inflammation NLR | [53] | Phase II on radiotherapy as primary treatment | NLR and clinical progression free survival or overall survival | 3.09 (1.64–5.82) | <0.001 |
2.16 (1.17–3.99) | 0.013 | ||||
Systemic inflammation PLR | [55] | Phase II study on radiotherapy as primary treatment | PLR and metastasis free survival or cancer specific survival or overall survival | 2.24 (1.06–4.76) | 0.036 |
3.99 (1.19–13.4) | 0.025 | ||||
1.87 (1.02–3.42) | 0.044 | ||||
SNP in RNASEL | [56] | Phase II study on radiotherapy as primary treatment | SNP of rs12757998 and biochemical recurrence | 0.60 (0.40–0.89) | 0.02 |
Systemic inflammation CRP | [57] | Phase II study on radiotherapy as primary treatment | CRP and cancer specific survival or overall survival | 3.36 (1.42–7.91) | 0.006 |
3.24 (1.84–5.71) | <0.001 |